Clinical Trial Update: Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin [Phase 4]

View source ↗

Summary

Phase 4 trial comparing thrice-daily versus twice-daily NovoMix 30 in type 2 diabetes patients inadequately controlled with basal insulin; results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2018-05-29